{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T05:14:24Z","timestamp":1731129264328,"version":"3.28.0"},"reference-count":39,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"11","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trans. Vis. Sci. Tech."],"published-print":{"date-parts":[[2024,11,8]]},"DOI":"10.1167\/tvst.13.11.6","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T16:30:50Z","timestamp":1731083450000},"page":"6","source":"Crossref","is-referenced-by-count":0,"title":["Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys"],"prefix":"10.1167","volume":"13","author":[{"given":"Kenzo","family":"Yamamura","sequence":"first","affiliation":[{"name":"Santen Pharmaceutical Co., Ltd. RD Center, Nara, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Mano","sequence":"additional","affiliation":[{"name":"Santen Pharmaceutical Co., Ltd. RD Center, Nara, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Fuwa","sequence":"additional","affiliation":[{"name":"Santen Pharmaceutical Co., Ltd. RD Center, Nara, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Iwamura","sequence":"additional","affiliation":[{"name":"UBE Corporation, Yamaguchi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Odani-Kawabata","sequence":"additional","affiliation":[{"name":"Santen Pharmaceutical Co., Ltd., Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/17469899.2021.1935241","article-title":"Omidenepag isopropyl ophthalmic solution for open-angle glaucoma and ocular hypertension: an update","volume":"16","author":"Aihara","year":"2021","journal-title":"Expert Rev Ophthalmol"},{"key":"bib2","doi-asserted-by":"crossref","first-page":"n1014","DOI":"10.1136\/bmj.n1014","article-title":"TAGS Study Group. Primary trabeculectomy for advanced glaucoma: pragmatic multicentre randomised controlled trial (TAGS)","volume":"373","author":"King","year":"2021","journal-title":"BMJ"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA"},{"key":"bib4","first-page":"1967","article-title":"Latanoprost in the treatment of glaucoma","volume":"8","author":"Alm","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s10384-020-00748-x","article-title":"Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-\/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study","volume":"64","author":"Aihara","year":"2020","journal-title":"Jpn J Ophthalmol"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"107836","DOI":"10.1016\/j.exer.2019.107836","article-title":"Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey","volume":"189","author":"Savinainen","year":"2019","journal-title":"Exp Eye Res"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1080\/14656566.2020.1795130","article-title":"Current and new pharmacotherapeutic approaches for glaucoma","volume":"21","author":"Shalaby","year":"2020","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"bib8","doi-asserted-by":"publisher","first-page":"e0181550","DOI":"10.1371\/journal.pone.0181550","article-title":"Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy","volume":"12","author":"Miki","year":"2017","journal-title":"PLoS One"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1167\/iovs.17-22745","article-title":"Pharmacologic characterization of omidenepag isopropyl, a novel selective EP2 receptor agonist, as an ocular hypotensive agent","volume":"59","author":"Kirihara","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1358\/dot.2019.55.6.2984806","article-title":"Omidenepag isopropyl for the treatment of glaucoma and ocular hypertension","volume":"55","author":"Ferro Desideri","year":"2019","journal-title":"Drugs Today"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/bph.14328","article-title":"Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma","volume":"176","author":"Impagnatiello","year":"2019","journal-title":"Br J Pharmacol"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1089\/jop.2017.0146","article-title":"Effects of a novel selective EP2 receptor agonist, omidenepag isopropyl, on aqueous humor dynamics in laser-induced ocular hypertensive monkeys","volume":"34","author":"Fuwa","year":"2018","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"bib13","doi-asserted-by":"publisher","first-page":"e0280331","DOI":"10.1371\/journal.pone.0280331","article-title":"Downregulation of COL12A1 and COL13A1 by a selective EP2 receptor agonist, omidenepag, in human trabecular meshwork cells","volume":"18","author":"Kumon","year":"2023","journal-title":"PloS One"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"4419","DOI":"10.1167\/iovs.02-1281","article-title":"Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide","volume":"44","author":"Richter","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"38913","DOI":"10.1074\/jbc.M111.252932","article-title":"Prostaglandin E2 induces matrix metalloproteinase 9 expression in dendritic cells through two independent signaling pathways leading to activator protein 1 (AP-1) activation","volume":"286","author":"Yen","year":"2011","journal-title":"J Biol Chem"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/IJG.0000000000001442","article-title":"Changes in prostaglandin-associated periorbital syndrome after switch from conventional prostaglandin F2a treatment to omidenepag isopropyl in 11 consecutive patients","volume":"29","author":"Nakakura","year":"2020","journal-title":"J Glaucoma"},{"issue":"8","key":"bib17","first-page":"e10064","article-title":"One-year follow-up study of changes in prostaglandin-associated periorbital syndrome after switch from conventional prostaglandin F2alfa to omidenepag isopropyl","volume":"12","author":"Oogi","year":"2020","journal-title":"Cureus"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1089\/jop.2020.0071","article-title":"Additive intraocular pressure-lowering effects of a novel selective EP2 receptor agonist, omidenepag isopropyl, combined with existing antiglaucoma agents in conscious ocular normotensive monkeys","volume":"37","author":"Fuwa","year":"2021","journal-title":"J Ocul Pharmacol Ther"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/IJG.0000000000001221","article-title":"Phase 2, randomized, dose-finding studies of omidenepag isopropyl, a selective EP2 agonist, in patients with primary open-angle glaucoma or ocular hypertension","volume":"28","author":"Aihara","year":"2019","journal-title":"J Glaucoma"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/IJG.0000000000001836","article-title":"A randomized phase 2 trial comparing omidenepag isopropyl 0.002% once and twice daily in subjects with primary open-angle glaucoma or ocular hypertension (SPECTRUM-6)","volume":"30","author":"Olander","year":"2021","journal-title":"J Glaucoma"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ajo.2020.06.003","article-title":"Omidenepag isopropyl versus latanoprost in primary open-angle glaucoma and ocular hypertension: the Phase 3 AYAME study","volume":"220","author":"Aihara","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1097\/IJG.0000000000002321","article-title":"Omidenepag isopropyl in latanoprost low\/non-responders with primary open-angle glaucoma or ocular hypertension: a phase 3, non-randomized, two-phase, open-label study","volume":"32","author":"Panarelli","year":"2023","journal-title":"J Glaucoma"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s10384-021-00868-y","article-title":"Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study","volume":"65","author":"Aihara","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"bib24","first-page":"1124","article-title":"Ability of SK&F 104078 and SK&F 104856 to identify alpha-2 adrenoceptor subtypes in NCB20 cells and guinea pig lung","volume":"259","author":"Gleason","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1124\/jpet.102.039057","article-title":"Yohimbine dimers exhibiting selectivity for the human alpha 2C-adrenoceptor subtype","volume":"303","author":"Lalchandani","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"5677","DOI":"10.1073\/pnas.91.12.5677","article-title":"Transcriptional down-regulation by insulin of the beta 3-adrenergic receptor expression in 3T3-F442A adipocytes: a mechanism for repressing the cAMP signaling pathway","volume":"91","author":"F\u00e8ve","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1476-5381.1993.tb13856.x","article-title":"Salmeterol, a long-acting beta 2-adrenoceptor agonist mediating cyclic AMP accumulation in a neuronal cell line","volume":"110","author":"McCrea","year":"1993","journal-title":"Br J Pharmacol"},{"key":"bib28","first-page":"976","article-title":"Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases","volume":"57","author":"Ishizaki","year":"2000","journal-title":"Mol Pharmacol"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1021\/bi702385k","article-title":"Inhibition of carbonic anhydrase II by thioxolone: a mechanistic and structural study","volume":"47","author":"Barrese","year":"2008","journal-title":"Biochemistry"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1177\/1087057106289403","article-title":"Inhibition profiling of human carbonic anhydrase II by high-throughput screening of structurally diverse, biologically active compounds","volume":"11","author":"Iyer","year":"2006","journal-title":"J Biomol Screen"},{"issue":"3","key":"bib31","doi-asserted-by":"publisher","first-page":"e92146","DOI":"10.1371\/journal.pone.0092146","article-title":"Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use","volume":"9","author":"Uitdehaag","year":"2014","journal-title":"PloS One"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1089\/jop.2023.0025","article-title":"Simultaneous effects of a selective EP2 agonist, omidenepag, and a rho-associated coiled-coil containing protein kinase inhibitor, ripasudil, on human orbital fibroblasts","volume":"39","author":"Hikage","year":"2023","journal-title":"J Ocul Pharmacol Ther"},{"key":"bib33","first-page":"315","article-title":"Ocular absorption and metabolism of topically applied epinephrine and a dipivalyl ester of epinephrine","volume":"17","author":"Wei","year":"1978","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib34","first-page":"897","article-title":"Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review","volume":"2","author":"Russo","year":"2008","journal-title":"Clin Ophthalmol"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1089\/jop.2010.0178","article-title":"Metabolism and ocular tissue distribution of an antiglaucoma prostanoid, tafluprost, after ocular instillation to monkeys","volume":"27","author":"Fukano","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejps.2018.07.034","article-title":"Esterase activity in porcine and albino rabbit ocular tissues","volume":"123","author":"Heikkinen","year":"2018","journal-title":"Eur J Pharm Sci"},{"key":"bib37","first-page":"1475","article-title":"Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues","volume":"43","author":"Schl\u00f6tzer-Schrehardt","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0939-6411(97)00064-7","article-title":"Ocular pharmacokinetics\/pharmacodynamics","volume":"44","author":"Worakul","year":"1997","journal-title":"Eur J Pharm Biopharm"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11095-022-03390-z","article-title":"Clinical ocular exposure extrapolation for ophthalmic solutions using PBPK modeling and simulation","volume":"40","author":"Le Merdy","year":"2023","journal-title":"Pharm Res"}],"container-title":["Translational Vision Science & Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2802221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T16:30:54Z","timestamp":1731083454000},"score":1,"resource":{"primary":{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2802221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1167\/tvst.13.11.6","relation":{},"ISSN":["2164-2591"],"issn-type":[{"value":"2164-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,8]]}}}